Home

PAUL VARKI

CIK 1677896 · Chief Legal Officer · last filed 2026-06-12

PAUL VARKI is a Chief Legal Officer who has filed 14 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing shows the insider had shares withheld for taxes covering $14.2K of AVTX on Jun 12, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $525.1K across reported positions. 9 SEC filings were submitted jointly with Cerecor Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$525.1K

Companies

2

Total Filings

14

Lifetime Open-Market Net

-$1.53M

Filer Profile

Reported Address
C/O AVALO THERAPEUTICS, INC.
1500 LIBERTY RIDGE DRIVE, SUITE 321
WAYNE, PA 19087
Related Filers
Cerecor Inc. — 9 joint filings, latest 2026-06-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AVTX Chief Legal Officer 32,576 $16.12 $525.1K -$1.51M 7 2026-06-12
Zyla Life Sciences (EGLT) Delisted SVP, GC & Chief Compliance Off 29,514 — — -$18.3K 6 2017-07-06

Recent Filings

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 AVTX Tax (F) −1,081 -$14.2K EDGAR
2026-05-26 AVTX Grant (A) +24,300 $0 EDGAR
2026-05-07 AVTX Mixed — -$573.3K EDGAR
2026-05-06 AVTX Notice (144) −92,771 -$1.51M EDGAR
2026-03-02 AVTX Grant (A) — $0 EDGAR
2025-12-12 AVTX Tax (F) −1,016 -$4.2K EDGAR
2025-01-30 AVTX Grant (A) — $0 EDGAR
2024-06-25 AVTX Grant (A) — $0 EDGAR
2017-07-06 Zyla Life Sciences (EGLT) Delisted Sell (S) −806 -$1.9K EDGAR
2017-06-12 Zyla Life Sciences (EGLT) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 14
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.